How ICER’s assessment of a new class of migraine treatments fails patients

Over 50 million Americans suffer from migraine and the majority of patients affected by this often debilitating disease are between 25 and 55 years old – the time they are most productive in their...
Read More
Aspen Spotlight Health: Discussing the forefront of innovation

For the second year in a row, PhRMA is proud to participate in Aspen’s Spotlight Health Conference. As the opening session of Aspen Ideas Festival, Spotlight Health welcomes over 1,500 experts and...
Read More
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B

Amidst debate about rising health care costs, some policy-makers have expressed renewed interest in using cost-effectiveness thresholds as the basis for setting coverage and payment policy. But a new...
Read More
ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches

A recent study conducted by the Academy of Managed Care Pharmacy (AMCP) and Xcenda found that 71 percent of insurers and 63 percent of biopharmaceutical companies surveyed were interested in...
Read More
Reality check: Value-based contracts are good for patients

Biopharmaceutical companies are joining stakeholders across the health care system to pursue flexible ways to pay for medicines that focus on results, lower out-of-pocket costs and enable patients to...
Read More
Video: Barriers to results-based contracts

Research suggests results-based contracts (RBCs)—also known as value-based contracts—have the potential to lower costs for patients and the health system. According to a recent analysis, these types...
Read More
Improving care quality by engaging patients in shared decision making

With the rapid movement towards value-based payment and delivery in health care, it is critical not to leave one of the key players behind: the patient.
Read More
ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access

To address rising health care costs and help patients better access new medicines, biopharmaceutical companies are sharing financial risk with payers through new payment arrangements, like...
Read More
Clarity around anti-kickback statute needed to promote innovative payment arrangements

You may have recently read about how biopharmaceutical companies and insurers are working together to implement new approaches to paying for medicines, including through results-based contracts...
Read More
Video: What is a results-based contract?

New medicines are revolutionizing how we fight disease, but too often patients have to fight to access innovative treatments. As part of the solution to this problem, biopharmaceutical companies are...
Read More